Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Yahoo! Finance
has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer in an ongoing U.S. Phase 1 clinical trial Received RMAT designation from the U.S. FDA for ronde-cel for the treatment of patients with relapsed or refractory LBCL receiving treatment in the second-line (2L) setting Announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of ronde-cel for the treatment of aggressive large B-cell lymphoma have been accepted for oral presentation at the ASH 67 th Annual Meeting and Exposition in December Announced the initiation of PiNACLE - H2H, a Phase 3 head-to-head CAR T-cell therapy clinical trial in aggressive large B-cell lymphoma in the 2L setting Formed a PiNACLE – H2H Steering Committee comprised of a distinguished group of lymphoma and cell therapy experts Cash of approximately
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]Seeking Alpha
- Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.MarketBeat
- Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and ExpositionGlobeNewswire
- Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
LYEL
Sec Filings
- 1/6/26 - Form 4
- 12/18/25 - Form 424B5
- 12/16/25 - Form EFFECT
- LYEL's page on the SEC website